Prodromal [Alzheimer's Disease](/diseases/alzheimers-disease) refers to the transitional stage between preclinical Alzheimer's disease and overt dementia, characterized by measurable cognitive decline and biomarker changes that precede functional impairment sufficient to meet dementia criteria. This stage represents a critical window for early intervention and therapeutic targeting.
Overview and Definition
Conceptual Framework
The Alzheimer's disease continuum has been conceptualized as a biological process that begins years before clinical symptoms emerge. Following the 2018 NIA-AA research framework, the disease is defined by biomarker evidence of [amyloid-beta](/proteins/amyloid-beta) (Aβ) pathology, [tau](/proteins/tau) pathology, or neurodegeneration, independent of clinical symptoms[@jack2018]:
Preclinical AD: Biomarker evidence of AD pathology in otherwise cognitively normal individuals
Mild Cognitive Impairment (MCI) due to AD: Cognitive decline in one or more domains that does not significantly impair daily activities
Prodromal AD: MCI due to AD with progressive cognitive decline that is still insufficient for dementia diagnosis
Dementia due to AD: Progressive cognitive decline impairing functional independence
The term "prodromal Alzheimer's" is often used interchangeably with "MCI due to AD" but emphasizes the progressive nature and imminent progression to dementia[@albert2011].
Epidemiology and Natural History
Prevalence
...
Prodromal Alzheimer's Disease
Prodromal [Alzheimer's Disease](/diseases/alzheimers-disease) refers to the transitional stage between preclinical Alzheimer's disease and overt dementia, characterized by measurable cognitive decline and biomarker changes that precede functional impairment sufficient to meet dementia criteria. This stage represents a critical window for early intervention and therapeutic targeting.
Overview and Definition
Conceptual Framework
The Alzheimer's disease continuum has been conceptualized as a biological process that begins years before clinical symptoms emerge. Following the 2018 NIA-AA research framework, the disease is defined by biomarker evidence of [amyloid-beta](/proteins/amyloid-beta) (Aβ) pathology, [tau](/proteins/tau) pathology, or neurodegeneration, independent of clinical symptoms[@jack2018]:
Preclinical AD: Biomarker evidence of AD pathology in otherwise cognitively normal individuals
Mild Cognitive Impairment (MCI) due to AD: Cognitive decline in one or more domains that does not significantly impair daily activities
Prodromal AD: MCI due to AD with progressive cognitive decline that is still insufficient for dementia diagnosis
Dementia due to AD: Progressive cognitive decline impairing functional independence
The term "prodromal Alzheimer's" is often used interchangeably with "MCI due to AD" but emphasizes the progressive nature and imminent progression to dementia[@albert2011].
Epidemiology and Natural History
Prevalence
MCI prevalence: 10-20% of adults over age 65
MCI due to AD: Approximately 50-60% of all MCI cases have AD pathology as the primary cause
Age distribution: Prevalence increases with age, rare before 65, more common after 75
Progression Rates
Annual conversion: Approximately 10-15% of MCI patients progress to dementia annually
Amnestic MCI: Higher conversion rate (15-20% annually), particularly those with memory-predominant deficits
Non-amnestic MCI: Lower conversion rates, more variable outcomes
Biomarker-positive MCI: Higher conversion rates (up to 40% annually for tau-positive individuals)[@petersen2018]
Clinical Features
Cognitive Characteristics
Memory Impairment
Episodic memory deficits, particularly for recent events
Difficulty learning and retaining new information
Often the earliest and most prominent deficit in amnestic presentations
Executive Function Deficits
Planning and organization difficulties
Reduced mental flexibility
Impaired problem-solving
Attention and Processing Speed
Reduced attention span
Slowed information processing
Difficulty with multitasking
Language and Visuospatial Changes
Word-finding difficulties (in more advanced prodromal stages)
Mild visuospatial deficits in some patients
Functional Status
Key distinction from dementia:
Independent daily living: Patients can perform complex instrumental activities of daily living (IADLs)
Mild functional changes: May require occasional reminders or assistance with complex tasks
[Petersen RC, Smith GE, Waring SC, et al, Mild cognitive impairment: clinical characterization and outcome (1999)](https://pubmed.ncbi.nlm.nih.gov/10190820/)
[Jack CR Jr, Bennett DA, Blennow K, et al, NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29653606/)
[Albert MS, DeKosky ST, Dickson D, et al, The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21514249/)
[Petersen RC, Lopez O, Armstrong MJ, et al, Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology (2018)](https://pubmed.ncbi.nlm.nih.gov/29282327/)
[Blennow K, Zetterberg H, Biomarkers for Alzheimer's disease: current status and prospects for the future (2018)](https://pubmed.ncbi.nlm.nih.gov/30051584/)
[Cummings J, Lee G, Ritter A, et al, Alzheimer's disease drug development pipeline: 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/36811460/)
[Sperling RA, Aisen PS, Beckett LA, et al, Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21514248/)